Active Recombinant Human FAS

Specification :
| Description : Fas and Fas Ligand (FasL) belong to the TNF superfamily and are type I and type II transmembrane proteins, respectively. Binding of FasL to Fas triggers apoptosis in Fas-bearing cells. The mechanism of apoptosis involves recruitment of pro-Caspase 8 through an adaptor molecule called FADD followed by processing of the pro-enzyme to active forms. These active Caspases then cleave various cellular substrates leading to the eventual cell death. sFasR is capable of inhibiting FasL-induced apoptosis by acting as a decoy receptor that serves as a sink for FasL. | Source : E. coli | Species : Human | Form : Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. | Bio-activity : Fully biologically active when compared to standard. The ED50 determined by its ability to inhibit the cytotoxicity of Jurkat cells is less than 15 μg/ml, corresponding to a specific activity of >66.7 IU/mg, in the presence of 2ng/ml of rHuFas Ligand. | Molecular Mass : 17.6 kDa | AA Sequence : RLSSKSVNAQ VTDINSKGLE LRKTVTTVET QNLEGLHHDG QFCHKPCPPG ERKARDCTVN GDEPDCVPCQ EGKEYTDKAH FSSKCRRCRL CDEGHGLEVE INCTRTQNTK CRCKPNFFCN STVCEHCDPC TKCEHGIIKE CTLTSNTKCK EEGSRSN | Endotoxin : Less than 1EU/μg of rHusFasR/TNFRSF6 as determined by LAL method. | Purity : >95% by SDS-PAGE and HPLC analyses. | Usage : This material is for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE. | Storage : This lyophilized preparation is stable at 2-8 centigrade, but should be kept at -20 centigrade for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 centigrade. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 centigrade to -70 centigrade. Avoid repeated freeze/thaw cycles. | Reconstitution : We recommend that this vial be briefy centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 centigrade. Further dilutions should be made in appropriate buffered solutions.